Koninklijke Phil (PHG) Stock News

Philips (NYSE: PHG) and Imricor Medical Systems (ASX: IMR) launched a new interventional MR (iMR) lab solution built around Philips’ high-performance 1.5T MRI platform and Imricor’s MR-compatible systems and consumables for cardiac interventions. The first commercially available configuration integrates Philips’ Cardiac MR Suite, including SmartHeart AI-powered planning and advanced cardiac imaging, with Imricor’s NorthStar iMR mapping and guidance system, Advantage-MR EP Recorder/Stimulator and Vision-MR electrophysiology catheters.

The solution enables MR-guided cardiac procedures with direct soft-tissue visualization and catheter tracking in a radiation-free iMR lab environment. It uses Philips’ BlueSeal helium-free MRI technology to reduce siting complexity and support installation near cardiology departments. According to Philips, the system is commercially available immediately in CE-marked markets and, in some configurations, in the U.S., and will be showcased at ESC Congress 2026 in Munich.

Philips (NYSE: PHG) has been selected for the U.S. ARPA-H Autonomous Interventions and Robotics (AIR) program and awarded up to US$33.7 million to advance AI-enabled robotic automation for stroke care. Philips will work with Johns Hopkins University, Boston University and clinical collaborator Dr. J Mocco of Weill Cornell Medicine.

The project focuses on remote-assisted and increasingly automated endovascular procedures on the Azurion image-guided therapy platform, developing technologies for robotic device control, endovascular navigation, image-based guidance, workflow automation and remote intervention. According to Philips, these technologies are under development and any future clinical use will depend on applicable regulatory requirements.

Philips (NYSE: PHG) has priced a EUR 650 million fixed-rate EU Green Bond under its EMTN program, consisting of 7.8-year notes due 2034, at 99.655% with a 4.0% coupon and 4.055% yield. The tranche was oversubscribed 2.7 times and is described as the healthcare industry's first EU Green Bond under the new European Green Bond Standard.

According to Philips, an amount equivalent to the gross proceeds will finance taxonomy-aligned economic activities outlined in its European Green Bond Factsheet, supporting its 2030 Impact Ambition. Net debt is not expected to increase, though gross debt will temporarily rise until repayment of a 2027 bond in May 2027. Settlement is scheduled for August 28, 2026, with listing sought on the Luxembourg Stock Exchange. Philips highlights current investment grade ratings of BBB+ (S&P), Baa1 (Moody’s) and BBB+ (Fitch), all with stable outlook.

Philips (NYSE: PHG) and Exor updated their long-term relationship agreement, allowing Exor to increase its shareholding in Philips up to 22% of issued ordinary share capital and voting rights, versus the previous 20% cap. Any stake above 22% remains subject to Philips’ Supervisory Board approval.

Governance arrangements are unchanged, including Exor’s right to nominate one Supervisory Board member. According to Philips, the update reflects Exor’s continued support for Philips’ 2026–2028 plan. Philips reported approximately EUR 18 billion in 2025 sales and about 63,700 employees worldwide.

Philips (NYSE: PHG) announced new collaborations with Blue Spark Technologies, Caretaker Medical, Cuviva, LifeSignals, Respiree and smartQare to expand its open patient monitoring ecosystem from hospital to home. The partners’ wearable and out-of-hospital solutions can integrate with Philips platforms such as the Patient Information Center (PIC) iX.

According to Philips, the ecosystem supports continuous, near real-time monitoring of parameters including temperature, non-invasive blood pressure, ECG, SpO₂, pulse, respiration, posture and activity, helping health systems coordinate care across higher-acuity settings and home. The portfolio is complemented by Philips Mobile Cardiac Telemetry (MCOT) for up to 30 days of post-discharge cardiac monitoring.

Philips (NYSE: PHG) launched the Philips Avent Share the Care Connector, an automated SMS-based tool that helps new moms organize and “activate” their support network during the postpartum period. Developed with insights from a March of Dimes survey, the tool lets moms invite supporters, set help preferences, choose a “Most Valuable Villager,” and send personalized prompts for tasks like meals, errands and emotional check-ins, while maintaining control over timing, participants and shared information. The solution is available online at the Share the Care website.

Summary not available.

Philips (NYSE: PHG) received FDA 510(k) clearance for its next-generation reusable SpO₂ clip sensor, designed to improve pulse oximetry reliability across diverse patient populations and clinical conditions. The sensor uses internal optical refinements to enhance signal quality and measurement consistency.

In desaturation studies, the sensor achieved an Accuracy Root Mean Square (ARMS) of 1.6%, compared with the 3% level recommended by ISO and recognized by the FDA. Accuracy varied by less than 0.5% between light and dark skin pigmentation groups in an SaO₂ range of 85–100%. The device is supported by Philips’ validation program aligned with FDA guidance and ISO/IEC standards and will be introduced in select global markets later this year. Philips reported 2025 sales of EUR 18 billion and operates in more than 100 countries.

Philips (NYSE:PHG) launched the Alturion ultrasound system, featuring AI-powered workflows for high-volume clinical environments. Alturion recently received FDA 510(k) clearance and CE mark, enabling availability in the USA and Europe.

The system offers advanced imaging, Elevate Plus AI measurements, and integration within Philips’ connected ultrasound ecosystem, sharing a common interface and interchangeable transducers with EPIQ Elite and Affiniti systems. Compatibility with Collaboration Live supports real-time remote ultrasound support, training and consultation across care settings.